Prognostic value of lymphocyte subsets in diffuse large B cell lymphoma

作者：Lihua Qiu, Lijing Xing, Meng Zhao, Biwen Sun, Xinpei Zhou, Min Li, Guoguang Ying, Huilai Zhang, Tian Chen · 发表于：Frontiers in Oncology · 年份：2025 · DOI：10.3389/fonc.2025.1671062 · 被引用次数：2 · 研究领域：Lymphoma Diagnosis and Treatment、CNS Lymphoma Diagnosis and Treatment、Cutaneous lymphoproliferative disorders research

Introduction: Although some clinical prognostic parameters and gene expression features have been identified to be associated with the prognosis of diffuse large B cell lymphoma (DLBCL), clinical outcomes of DLBCL remains unpredictable. Lymphocyte subpopulations are considered to be prognostic factors for DLBCL, however due to the small sample size, conflicting views exist. Methods: 301 newly diagnosed DLBCL patients treated at our center from January 2015 to December 2019 were retrospectively analyzed to explore the relationship of lymphocyte subsets and prognosis prediction. Results: In this retrospective single-center study, patients with more severe disease, defined by either advanced Ann Arbor stage or a high-risk IPI score, consistently exhibited significantly lower percentages of CD19+ B cells, CD4+ T cells and CD4+/CD8+ ratio, while percentage of CD8+ T cells were significantly higher. There were no significant differences in percentages of CD3+ T cells and CD16+CD56+ NK cells. Correlation analysis revealed significant associations between lymphocyte subsets and clinical features such as Ann Arbor stage, IPI score, lactate dehydrogenase (LDH), beta-2 microglobulin (b2-MG), Ki-67, age, and neutrophils. Higher percentages of CD19+ B cells, CD4+ T cells, and CD16+CD56+ NK cells, a higher CD4+/CD8+ ratio, and a lower percentage of CD8+ T cells at diagnosis predicted good response after R-CHOP treatment. Multivariate analysis indicated that a low CD4+/CD8+ ratio was indepe...